

DAFTAR PUSTAKA

1. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy : Part 1 : Recommendations for diagnosis , rehabilitation , orthopedic and nutritional care. 2018;28:103–15. .
2. Arnold WD, Kassar D, and Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. *Muscle Nerve*. 2015;51 (2):157-167.
3. Ashrafzadeh F, Nabvi AS, Asadian N, Akhondian J, and Toosi MB. Spinal muscular atrophy: a short review. *IJP*. 2014;2:211-5.
4. Baloni MTC and Ambiel CR. Spinal muscular atrophy: diagnosis, treatment and future prospects. *J Pediatr (Rio J)*. 2010;86:261-70.
5. Calder AN, Androphy EJ, Hodgetts KJ. Small molecules in development for the treatment of spinal muscular atrophy. *Journal Med Chem*. 2016;59:10067-83.
6. Shorrock HK and Gillingwater TH. Development and translation of therapies for spinal muscular atrophy. *European Medical Journal*. 2016;4:64-73.
7. Akutsu T, Nishio H, Sumino K, Takeshima Y, Tsuneishi S, Wada H, et al. Molecular Genetics of Spinal Muscular Atrophy: Contribution of the *NAIP* Gene to Clinical Severity. *Kobe J. Med. Sci*. 2002;48:25-31.
8. Monani UR. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron disease. *Neuron*. 2005;48:885-896.
9. Tsai L, Therapy Development for Spinal Muscular Atrophy in SMN Independent targets. *Neural plasticity*. 2012;1-10.
10. Kissel JT, Scoot CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, et al. SMA carnival trial part II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. *Plos One*. 2011;6:1-11.
11. Lewelt A, Newcomb TM, Swoboda KJ. New therapeutic approaches to spinal muscular atrophy. *Curr Neurol Neurosci Rep*. 2012;12(1):42–53.

12. Dastur R S., Gaitonde P S., Khadilkar S V., Udani V P., and Nadkarni J J. 2006. Correlation between deletion patterns of SMN and NAIP genes and the clinical features of spinal muscular atrophy in Indian patients. *Neurology India*, 53 (3) pg 255-259
13. Lewelt AJ, Krosschell KJ, Scott C, Sakonju A, Kissel JT, et all. Compound muscle action potential and motor function in children with spinal muscular atrophy. *Muscle Nerve*. 2010;42:703-8.
14. Pruss RM, Paoli MG, Morozova S, Berna P, Abitbol JL, and Bordet T. Drug discovery and development for spinal muscular atrophy: lesson from screening approaches and future challenges for clinical development. *Perspective*. 2010;2:1429-40.
15. Lorson CI, Rindt H, and Shababi M. Spinal muscular atrophy: mechanism and therapeutic strategies. *Human Molecular Genetics*. 2010;1:111-8.
16. Nurputra DK, Lai PS, Harahap NIF, Morikawa S, Yamamoto T, Nishimura N, et al. Spinal Muscular Atrophy: From Gene Discovery to Clinical Trials. *Am J Hum Genet*. 2013;77:435-463
17. Saito T, Nurputra DK, Harahap NIF, Harahap ISK, Yamamoto H, Muneshige E, et all. A study valproic acid for patients with spinal muscular atrophy. *Neurology and Clinical Neuroscience*. 2014;3:49-57.
18. Cung BH, Wong VC. Spinal Muscular Atrophy: Survival Pattern and Functional status. *Pediatrics*. 2004;114:e548-553.
19. Exhibits E. Scoliosis Imaging : What Radiologists. 2010;(2006).
20. Parr A, Askin G. Paediatric scoliosis Update on assessment and treatment. 2020;49(12):832–7.
21. Carter GT, Abresch RT, Fowler WM, Johnson ER, Kilmer DD, McDonald CM. Spinal Muscular Athrophy type II and III. *Am J Physical Med*.1995;1-5
22. Wang HY, Ju YH, Chen SM, Lo SK, Jong YJ. Joint range of motion limitations in children and young adults with spinal muscular atrophy. *Arch Phys Med Rehabil*.2004;85(10):1689-93.

23. Iannaccone, ST. Outcome measures for pediatric spinal muscular atrophy. *AmSMART*.2002.
24. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. 2007;22(8):1027–49.
25. Darbar IA, Plaggert PG, Resende MBD, Zanoteli E, and Reed UC. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. *BMC Neurology*. 2011;11:1-5.
26. Weiss HR, Negrini S, Rigo M, Kotwicki T, Hawes MC, Grivas TB, et al. Indications for conservative management of scoliosis (guidelines). *Scoliosis*. 2006;1-5.
27. Grondard C, Biondi O, Armand AS, Lecolle S, Della-Gaspera BD, Pariset C, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy. *J Neurosci*.2005;25:7615-22.
28. Weppeler CH, Magnusson SP. Increasing Muscle Extensibility: A Matter of Increasing Length or Modifying sensation?.*PhysTher*.2010;90:438-449.
29. Montes J, Gordon AM, Pandya S, DeVivo DC, Kaufmann P. Clinical Outcome Measures in Spinal Muscular Atrophy. *J child Neurol*. 2009;8:968-978.
30. Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, et all. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. *Muscle Nerve*. 2014;49:187-92.
31. Kartasasmita C B, Dahlan Z, Garna H, Setiabudiawan B. Vaksin pneumokokus. *Vaksin anak dan dewasa* edisi ke-2;87-90.
32. Hendarto A, Sjarif DR. Antropometri pada anak dan remaja. *Buku Ajar Nutrisi Pediatrik dan Metabolik*.2011;3:23-35.
33. Collin C, Wade DT, Davies S, Horne V,. The Barthel ADL Index: a reliability study, *Int.Disabil.Stud*. 1988; 10(2), 61-63

34. Keputusan Menteri Kesehatan Republik Indonesia. Standar Antropometri penilaian status gizi anak. No 1995/MENKES/SK/XII/2010
35. Varni JW, Seid M, Kurtin PS. The PedsQL 4.0: Measurement model for the pediatric quality of life inventory. *Quality of life research*.2006;15(2):203-215.
36. Pedoman Teknis Penilaian Rumah Sehat, Departemen Kesehatan RI, 2005.